

each R_1 is independently selected from the group consisting of H; halogen; C_{1-4} alkyl; C_{1-4} alkenyl; C_{1-4} alkynyl; $--COR_4$ where R_4 is H, C_{1-4} alkyl or C_{1-4} alkoxy; C_{3-6} cycloalkyl; aryl; heteroaryl; cyano; nitro; trihalomethyl; oxo; or $-(CH_2)_n-X-(CH_2)_m-(R_5)_o$ where X is O, S or N, n is 0-3, m is 0-3, o is 0-1, and R_5 is methyl or H_{1-2} ;

each R_2 and each R_3 are independently selected from the group consisting of H; halogen; C_{1-4} alkyl; C_{1-4} alkenyl; C_{1-4} alkynyl; $--COR_4$ where R_4 is H, C_{1-4} alkyl or C_{1-4} alkoxy; C_{3-6} cycloalkyl; aryl; heteroaryl; cyano; nitro; trihalomethyl; oxo; or $-(CH_2)_n-X-(CH_2)_m-(R_5)_o$ where X is O, S or N, n is 0-3, m is 0-3, o is 0-1, and R_5 is methyl or H_{1-2} ; or an R_2 and an R_3 together comprise a saturated, partly saturated, or unsaturated ring structure having the formula $-(C(R_6)_p)_q-X_s-(C(R_6)_p)_r-X_t-(C(R_6)_p)_u$ where each R_6 is independently selected from the group consisting of H; halogen; C_{1-4} alkyl; C_{1-4} alkenyl; C_{1-4} alkynyl; $--COR_4$ where R_4 is H, C_{1-4} alkyl or C_{1-4} alkoxy; C_{3-6} cycloalkyl; aryl; heteroaryl; cyano; nitro; trihalomethyl and oxo where each p is independently 1 or 2, q is 0-5, r is 0-5, u is 0-5; each X is independently O, S, or N and s is 0 or 1; provided that $q + r + u + s + t$ is less than 6;

Y is selected from the group consisting of O; S; N; $-(C(R_7)_z)_s$ —where each R_7 is independently as previously defined for R_1 , each z is independently 1-2, and s is 1-3; $--CH=$; $--CH=CH--$; or Y_1CH_2 —where Y_1 is O, N, or S; and the dotted lines are optional double bonds, with the proviso that if the ring including Y is a cyclohexane ring or a heterocyclic 5 member ring said ring is not fully unsaturated, and that if Y is O, N or S, the ring including Y contains at least one said double bond,

said compound further having selective agonist activity at the $\alpha 2B$ or $\alpha 2B/\alpha 2C$ adrenergic receptor subtype(s) over the $\alpha 2A$ adrenergic receptor subtype, and all pharmacologically acceptable salts, esters, stereoisomers and racemic mixtures thereof.

2. (Amended) The compound of claim 1 in which the ring including Y has either a single double bond or no double bond, except that when an R_2 and an R_3 together comprise a saturated, unsaturated or partly saturated ring structure said Y-including ring optionally shares an additional double bond with said condensed ring, provided Y is not S, O, or N.

AB

9. (Amended) The compound of claim 2, in which each R_2 and each R_3 are independently selected from the group consisting of: H; C_{1-4} alkyl; C_{1-4} alkenyl; C_{1-4} alkynyl; halide; trihalomethyl; cycloalkyl; $(CH_2)_n-X-(CH_2)_m-(R_5)_o$, where X is O, S or N, n is 0-3, m is 0-3, o is 0-1, and R_5 is methyl or H_{1-2} ; or an R_2 and an R_3 together comprise a saturated, partly saturated, or unsaturated ring structure having the formula $-(C(R_6)_p)_q-X_s-(C(R_6)_p)_r-X_t-(C(R_6)_p)_u$ where each R_6 is independently selected from the group consisting of H; halogen; C_{1-4} alkyl; C_{1-4} alkenyl; C_{1-4} alkynyl; $--COR_4$ where R_4 is H, C_{1-4} alkyl or C_{1-4} alkoxy; C_{3-6} cycloalkyl; aryl; heteroaryl; cyano; nitro; trihalomethyl; and oxo where each p is independently 1 or 2, q is 0-4, r is 0-4, u is 0-4; each X is independently O, S, or N, s is 0 or 1, and $q + s + r + t + u = 3$ or 4.

Sub B2

10. (Amended) The compound of claim 3, in which each R_2 and each R_3 are independently selected from the group consisting of: H; C_{1-4} alkyl; C_{1-4} alkenyl; C_{1-4} alkynyl; halide; trihalomethyl; cycloalkyl; $(CH_2)_n-X-(CH_2)_m-(R_5)_o$, where X is O, S or N, n is 0-3, m is 0-3, o is 0-1, and R_5 is methyl or H_{1-2} ; or an R_2 and an R_3 together comprise a saturated, partly saturated, or unsaturated ring structure having the formula $-(C(R_6)_p)_q-X_s-(C(R_6)_p)_r-X_t-(C(R_6)_p)_u$ where each R_6 is independently selected from the group consisting of H; halogen; C_{1-4} alkyl; C_{1-4} alkenyl; C_{1-4} alkynyl; $--COR_4$ where R_4 is H, C_{1-4} alkyl or C_{1-4} alkoxy; C_{3-6} cycloalkyl; aryl; heteroaryl; cyano; nitro; trihalomethyl; and oxo where each p is independently 1 or 2, q is 0-4, r is 0-4, u is 0-4; each X is independently O, S, or N, s is 0 or 1, and $q + s + r + t + u = 3$ or 4.

A4 Sub B3

71. (Amended) The compound of claim 53 in which an R_2 and an R_3 together comprise a saturated, partly saturated, or unsaturated ring structure having the formula $-(C(R_6)_p)_q-X_s-(C(R_6)_p)_r-X_t-(C(R_6)_p)_u$ where each R_6 is independently selected from the group consisting of H; halogen; C_{1-4} alkyl; C_{1-4} alkenyl; C_{1-4} alkynyl; $--COR_4$ where R_4 is H, C_{1-4} alkyl or C_{1-4} alkoxy; C_{3-6} cycloalkyl; aryl; heteroaryl; cyano; nitro; trihalomethyl; and oxo where each p is independently 1 or 2, q is 0-4, r is 0-4, u is 0-4; each X is independently O, S, or N, s is 0 or 1, and $q + s + r + t + u = 3$ or 4.